Acromegaly
NEJM 393:1926-1939, Giustina,A. & Colao,A.,, 2025
A 41-year-old man with Thunderclap Headache
Neurol 91:e87-e91, Grossman, S.et al, 2018
NT-3 Promotes Nerve Regeneration and Sensory Improvement in CMT1A Mouse Models and in Patients
Neurol 65:681-689, 662, Sahenk,Z.,et al, 2005
Recombinant Human Nerve Growth Factor in the Treatment of Diabetic Polyneuropathy
Neurol 51:695-702, 6621998., Apfel,S.C.,et al, 1998
Long-Term Octreotide Therapy in Growth Hormone-Secreting Pituitary Adenomas:Evaluation with Serial MR
AJNR 18:765-772, Lundin,P.,et al, 1997
Nerve Growth Factor and Diabetic Neuropathy
Lancet 348:1044-1045, Dyck,P.J., 1996
Neurofibromatosis 2 (Bilateral Acoustic Neuro-fibromatosis)
NEJM 318:684-688, Martuza,R.L.&Eldridge,R., 1988
Retrospective Review of Cerebral Mycotic Aneurysms in 26 Patients: Focus on Treatment in Strongly Immunocompromised Patients with a Brief Literature Review
AJNR 34:823-827, Allen, L.M.,et al, 2013
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
Rapidly Progressive Dementia in a Man With HIV Infection and Undetectable Plasma Viral Load
Neurol 100:344-348, Chishimba,L.C.,et al, 2023
HIV Infection - Screening, Diagnosis, and Treatment
NEJM 384:2131-2143, Saag, M.S., 2021
HIV-Associated CD8 Encephalitis: A UK Case Series and Review of Histopathologically Confirmed Cases
Front Neurol 12:628296, Lucas,S.B.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
NEJM 380:1597-1605, Cortese, I.,et al, 2019
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Clinicopathologic Conference Cryptococcal Meningitis in a Patient with Chronic HIV Infection
NEJM 376:1065-1071, Case 8-2017, 2017
Zika Virus
NEJM 374:1552-1563, Petersen, L.R.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
A Young Woman with Blurred Vision and Distal Paresthesias
JAMA Neurol 72:1519-1523, Kung, N.H.,et al, 2015
A 48-year-old Man with Walking Difficulty
Neurol 85:e165-e169, Kalladka, D.,et al, 2015
Nocardiosis of the Central Nervous System
Medicine 93:19-32, Anagnostou, T.,et al, 2014
HIV Testing and Management of Newly Diagnosed HIV
BMJ 349:g4275, Rayment, M.,et al, 2014
Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014
Impact of Late Diagnosis and Treatment on Life Expectancy in People with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
BMJ 343:d6016,d6015, May, M.,et al, 2011
Glucose Transporter-1 Deficiency Syndrome: The Expanding Clinical and Genetic Spectrum of a Treatable Disorder
Brain 133:655-670, Leen,W.G., et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Coccidioidal Meningitis: Clinical Presentation and Management in the Fluconazole Era
Medicine 89:251-284, Mathisen,G.,et al, 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009
Changes in the Incidence and Predictors of Human Immunodeficiency Virus-Associated Dementia in the Era of Highly Active Antiretroviral Therapy
Ann Neurol 63:213-221, Bhaskaran,K.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Corticosteroids for Acute Bacterial Meningitis
NEJM 357:2507-2509, Greenwood,B.M., 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
HIV-associated Neurologic Disease Incidence Changes: Multicenter AIDS Cohort Study, 1990-1998
Neurol 56:257-260, Sacktor,N.,et al, 2001
Primary Lymphoma of the Pituitary: An Emerging Clinical Entity
J Clin Endocrinol Metab 86:4567-4575, Giustina,A.,et al, 2001
Role of Brain Biopsy in the Management of Focal Brain Lesions in HIV-Infected Patients
Neurol 54:993-997, Antinori,A.,et al, 2000
Adverse Effects of Antiretroviral Therapy
Lancet 356:1423-1430, Carr,A. &Cooper, D.A., 2000
Further Evolution Toward Effective Therapy for Acute Ischemic Stroke
JAMA 279:1298-1303, 13041998., Fisher,M.&Bogousslavsky,J., 1998
Synergistic Immunomod Effects of Interferon-Beta1b & Phosphodiesterase Inhib Pentoxifylline in Pts with Relapsing-Remit MS
Ann Neurol 44:27-34, 71998., Weber,F.,et al, 1998
Central Nervous System Infection with Listeria Monocytogenes
Medicine 77:313-316, Mylonakis,E.,et al, 1998
Epidemiology, Pathophysiology, & Management of Hyponatremic Encephalopathy
Am J Med 102:67-77, Fraser,C.L.,et al, 1997
Neurological Complications of HIV Infection
Lancet 348:445-452, Price,R.W., 1996
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
Timing of Vulnerability of the Brain to Iodine Deficiency in Endemic Cretinism
NEJM 331:1739-1744, 17701994., Xue-Yi,C.,et al, 1994